Drug intelligence / Profile preview

octavalent human papillomavirus vaccine

Development stage: Unknown
Lead developer: Merck
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

The octavalent human papillomavirus vaccine is a prophylactic vaccine designed to prevent Human Papillomavirus (HPV) infection. It is an L1 Virus-Like Particle (VLP) vaccine, meaning it contains non-infectious protein shells that mimic the outer coat of eight different HPV types, thereby stimulating an immune response without exposing the recipient to viral genetic material. The vaccine is formulated with adjuvants, specifically amorphous aluminum hydroxyphosphate sulfate (AAHS) and ISCOMATRIX™ (IMX), to enhance its immunogenicity. It is being developed by Merck Sharp & Dohme LLC.

Other names: Octavalent HPV L1 Virus-Like Particle (VLP) vaccine

Targets

HPV L1 (Human papillomavirus L1 capsid protein)

Beyond the preview

Go deeper on octavalent human papillomavirus vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on octavalent human papillomavirus vaccine.

Explore the full profile